吉非替尼与埃克替尼治疗晚期EGFR突变非小细胞肺癌的比较  

Comparison of Gefitinib and Ektinib in the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

作　　者：陈胜佳[1] 林金兰[1] 朱凯[1] 徐振武[1] 庄武[1] 苗茜[1] 蒋侃[1] CHEN Shengjia;LIN Jinlan;ZHU Kai;XU Zhenwu;ZHUANG Wu;MIAO Qian;JIANG Kan(Department of Chest Medicine,Fujian Cancer Hospital,Fuzhou Fujian 350001,China)

机构地区：[1]福建省肿瘤医院胸部内科

出　　处：《中国卫生标准管理》2019年第14期73-75,共3页China Health Standard Management

摘　　要：目的探讨吉非替尼与埃克替尼对晚期表皮生长因子受体(EGFR)突变型非小细胞肺癌患者疗效、不良反应及对肺功能的影响。方法本次实验选择2014年5月-2017年11月在我院实施治疗的晚期EGFR突变型非小细胞肺患者,共计100例,并按照不同的治疗方法分为两组,开展对比实验。对照组采用吉非替尼方案治疗,观察组采用埃克替尼治疗,两组均进行2周期治疗,治疗完毕后对患者效果进行评估。根据实体瘤疗效评价标准(RECIST)的完全缓解(CR)、部分缓解(PR)、未完全缓解(IR)、疾病稳定(SD)及疾病进展(PD)对患者疗效率进行评估;采用platinumEliteDL型肺功能测定仪测定对治疗前后的结果进行分析,其主要指标包括FEV1、FVC、FEV1/FVC水平等,随后,则分析患者治疗后肺部功能的改善情况,以及临床症状的缓解效果。结果两组患者治疗后的缓解率(72.00%vs.70.00%)比较无统计学意义(P>0.05)。两组患者治疗后的FEV1、FVC水平高于治疗前,差异具有统计学意义(P<0.05),但两组间比较差异无统计学意义(P>0.05)。同时,两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论晚期EGFR突变型非小细胞肺癌患者采用埃克替尼与吉非替尼治疗的疗效相当。Objective To investigate the efficacy,side effects and lung function of gefitinib and enetinib in patients with advanced epidermis growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC).Methods 100 patients with advanced EGFR mutant non-small cell lung treated in our hospital from May 2014 to November 2017 were selected and divided into two groups according to the different treatment methods.The control group was treated with gefitinib regimen,and the observation group was treated with etinib.Both groups were treated with 2 cycles of treatment,and the effect of the patients was evaluated after treatment.According to solid tumor therapy Effect evaluation standard(RECIST)complete remission(CR),partial remission(PR),did not completely alleviate(IR),disease stability(SD)and disease progress(PD)to evaluate the therapeutic efficiency of the patients.The results before and after treatment were analyzed by platinumEliteDL pulmonary function tester.The main indexes included the level of FEV1,FVC,FEV1/FVC,and then the improvement of pulmonary function after treatment and the remission effect of clinical symptoms were analyzed.Results The remission rate of the two groups after treatment(72.00%vs.70.00%)There was no significant difference between the two groups(P>0.05).The level of FEV1,FVC in the two groups after treatment was significantly higher than that before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).At the same time,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of etinib and gefitinib in the treatment of advanced EGFR mutant non-small cell lung cancer is the same as that of gefitinib.

关 键 词：表皮生长因子受体突变 埃克替尼 吉非替尼 晚期非小细胞肺癌 临床疗效 

分 类 号：R973[医药卫生—药品]